Global Pharmaceutical Drugs Market Briefing 2018

Pharmaceutical Drugs Market Global Briefing 2018 provides strategists, marketers and senior management with the critical information they need to assess the global pharmaceutical drugs sector.

The pharmaceutical industry develops drugs to diagnose, cure, treat or prevent diseases. Pharmaceutical companies produce both generic and branded drugs. Pharmaceutical drugs are subjected to various laws and regulations that deal with patenting, testing, safety, efficacy and marketing.

Pharmaceutical companies produce pharmaceutical drugs made from active pharmaceutical ingredients (API) and excipients.

North America was the largest region in the pharmaceutical drugs market in 2017, accounting for around 37% market share. Asia Pacific was the second largest region accounting for around 22% market share. Western Europe was the third largest region accounting for around 20% market share.

Early Rx-To-OTC Switch - Early Rx-to-OTC switch, or switching the product from prescription to non-prescription status, is a key trend in the dermatology drugs market. Traditionally, the Rx-to-OTC status conversion was generally observed at a phase nearing the patent expiry or after. However, forward-thinking companies are now looking at switching from Rx-to-OTC well in advance of the patent expiry of the drug. This helps the manufacturer to capitalize on the market opportunities for the product. Early Rx-to-OTC switching also provides an additional benefit as a way to recover all the expenses incurred on the product by the company.

A key example from the dermatology OTC drugs market for an early switch includes butenafine hydrochloride (Lotrimin Ultra), an anti-fungal drug. The product was reclassified and switched to being an OTC drug in December 2001, long before its patent expiry (April 2017). It is used in the treatment of athlete's foot, jock itch and ringworm infections.

Scope:

> Markets Covered: Cardiovascular Drugs, Musculoskeletal Drugs, Oncology Drugs, Anti-infective Drugs, Metabolic Disorder Drugs, Central Nervous System Drugs, Genito-urinary Drugs, Gastrointestinal Drugs, Respiratory Drugs, Hematology Drugs, Dermatology Drugs, Ophthalmology Drugs.

> Time Series: Five years historic and forecast.

> Data: Market value in $ billions.

> Data Segmentations: Regional breakdowns, market share of competitors, key sub segments.

> Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Companies Mentioned

Novartis AG

Sanofi S.A.

F. Hoffmann-La Roche Ltd

Pfizer Inc.

Gilead Sciences Inc.

Johnson & Johnson

GlaxosmithKline Plc.

Bayer AG

Teva Pharmaceuticals

Merck & Co